Company Filing History:
4 out of 4 
1 out of 5 Years Active: 2019-2021
Title: Innovations of Alexandra Kuznetsova: Pioneering Patents in Cancer Treatment
Introduction: Alexandra Kuznetsova is a distinguished inventor based in Natick, MA, who has made significant contributions to the field of medical science through her innovative research and patented inventions. With a total of four patents, her work has primarily focused on the treatment of neoplasms and specific kinase inhibition.
Latest Patents: One of Kuznetsova's latest patents is titled "Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors." This invention presents novel compositions and methods aimed at treating neoplasms by specifically targeting quiescent cancer cells with therapeutic agents. The approach emphasizes the importance of combining these treatments with other effective anti-cancer therapies utilizing EGFR inhibitor agents. Another significant patent is her work on "Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases." This invention relates to specific compounds and their uses as medicaments, highlighting their potential in pharmaceutical applications.
Career Highlights: Throughout her career, Alexandra Kuznetsova has gained valuable experience working with prominent organizations such as Felicitex Therapeutics, Inc. and Selvita S.a. Her role in these companies has allowed her to further her research and develop groundbreaking solutions in the medical and pharmaceutical fields.
Collaborations: In her journey as an inventor, Kuznetsova has collaborated with talented professionals, including Maria Vilenchik and Michael Frid. These collaborations have enriched her work and contributed to her success in developing innovative patents that address critical challenges in cancer treatment.
Conclusion: Alexandra Kuznetsova stands out as a dedicated inventor whose patents have the potential to make a remarkable impact on cancer therapies. Her innovative approaches to targeting neoplasms and inhibiting specific kinases demonstrate her commitment to advancing medical science and improving treatment options for patients in need.